This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Prostate Disease  • Oncology  • Prostate Cancer  • Alert me on articles by topic

Mike Mitka

JAMA. 2004;292:2326-2327.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In recent years, a prostate-specific antigen (PSA) test has become a common route to uncovering prostate cancer in the United States. The American Cancer Society recommends that physicians should offer PSA testing and digital rectal examination annually beginning at age 50 years in men who have at least a 10-year life expectancy; men at high risk should begin testing at age 45 years.

But now, an expert regarded as the father of PSA testing says that it is no longer a useful tool in screening and diagnosing prostate cancer and, in fact, may be causing unwarranted treatment for a typically slow-growing tumor that kills only 226 of every 100 000 men older than 65 years.

Physicians should discuss with patients the implications of prostate-specific antigen and its use in prostate cancer screening, including such issues as potential harms and benefits and the likelihood of various outcomes. Photo credit: . . . [Full Text of this Article]

CONSEQUENCES OF OVERSCREENING?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Educating African American Men about the Prostate Cancer Screening Dilemma: A Randomized Intervention.
Taylor et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:2179-2188.
ABSTRACT | FULL TEXT  

No One Dies From Prostate Cancer?--Reply
Concato and Wells
Arch Intern Med 2006;166:1526-1526.
FULL TEXT